BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36871138)

  • 1. A Structured Process to Identify Fit-for-Purpose Study Design and Data to Generate Valid and Transparent Real-World Evidence for Regulatory Uses.
    Gatto NM; Vititoe SE; Rubinstein E; Reynolds RF; Campbell UB
    Clin Pharmacol Ther; 2023 Jun; 113(6):1235-1239. PubMed ID: 36871138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework.
    Gatto NM; Campbell UB; Rubinstein E; Jaksa A; Mattox P; Mo J; Reynolds RF
    Clin Pharmacol Ther; 2022 Jan; 111(1):122-134. PubMed ID: 34716990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real-World Evidence for Regulatory Decisions.
    Gatto NM; Reynolds RF; Campbell UB
    Clin Pharmacol Ther; 2019 Jul; 106(1):103-115. PubMed ID: 31025311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building trust in real world evidence (RWE): moving transparency in RWE towards the randomized controlled trial standard.
    White R
    Curr Med Res Opin; 2023 Dec; 39(12):1737-1741. PubMed ID: 37787381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review.
    Khambholja K; Gehani M
    Value Health; 2023 Mar; 26(3):427-434. PubMed ID: 36210293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward a better understanding about real-world evidence.
    Liu M; Qi Y; Wang W; Sun X
    Eur J Hosp Pharm; 2022 Jan; 29(1):8-11. PubMed ID: 34857642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms.
    Beyrer J; Abedtash H; Hornbuckle K; Murray JF
    J Comp Eff Res; 2022 May; 11(7):499-511. PubMed ID: 35296149
    [No Abstract]   [Full Text] [Related]  

  • 10. HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force.
    Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ
    Value Health; 2022 Oct; 25(10):1663-1672. PubMed ID: 36241338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force.
    Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ
    Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):44-55. PubMed ID: 36215113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims.
    Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ
    Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments.
    Schneeweiss S; Patorno E
    Endocr Rev; 2021 Sep; 42(5):658-690. PubMed ID: 33710268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate 'Real World' Evidence of Comparative Effectiveness and Safety.
    Wang SV; Patterson OV; Gagne JJ; Brown JS; Ball R; Jonsson P; Wright A; Zhou L; Goettsch W; Bate A
    Drug Saf; 2019 Nov; 42(11):1297-1309. PubMed ID: 31452075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.
    Patorno E; Schneeweiss S; Wang SV
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 3(Suppl 3):45-59. PubMed ID: 32250527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies.
    Burns L; Kalesnik-Orszulak R; Spring R; Zeegers F; Rutstein M; Hukkelhoven M; Wruck L; O'Donnell J
    Adv Ther; 2022 Oct; 39(10):4772-4778. PubMed ID: 35972721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.